Roche has struck an obesity-focused pact with Rona Therapeutics, gaining global rights to a Rona RNA interference program targeting ALK7, a genetically validated obesity and metabolic indication. The arrangement adds to Roche’s growing China and obesity deal momentum, with the deal positioned around lowering visceral fat and expanding the company’s obesity pipeline beyond GLP-1-centric mechanisms. The agreement highlights renewed investor and pharma interest in ALK7 inhibition as a differentiated obesity target. With competing ALK7 efforts already active across large pharma and RNAi specialists, Roche is betting that RNAi delivery can translate target biology into clinically meaningful outcomes. For biotech partners, the deal also underlines how obesity remains a top external partnering priority—especially for assets that can be framed around validated genetics and potentially distinct mechanisms of action.